Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Breeze Meds

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Breeze Meds head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 37 · Grade C

Breeze Meds

Visit Breeze Meds Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 76 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Breeze Meds a bad call — it's best for readers starting at a low dose who want nothing charged until a provider has approved them. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
70
Supply Reliability
88
82
Transparency
84
60
Access Breadth
82
88
Clinical Oversight
88
78
Track Record
90
76
Invigor MedicalBrief Score 88 · 76Breeze Meds

Price, coverage & the tracker

Invigor MedicalBreeze Meds
Brief Score88/100 (B+)76/100 (C)
Semaglutide$199/moFrom $199/mo injectable · $299/mo oral (lowest dose)
Tirzepatide$339/moFrom $399/mo injectable · $399/mo oral (lowest dose)
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Breeze Meds: ⚠ Every published figure is quoted at the LOWEST dose — the funnel says higher doses may cost more, so these are floors.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.